KODIAK SCIENCES INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $106.00K, a 29.27% increase year-over-year.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $82.00K, a 38.98% increase year-over-year.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $59.00K, a 54.96% decline year-over-year.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $131.00K, a 104.69% increase year-over-year.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $180.00K, a 68.22% increase from fiscal 2024.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $107.00K, a 41.21% decline from fiscal 2023.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $182.00K, a 4.60% increase from fiscal 2022.
- KODIAK SCIENCES INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $174.00K, a 64.05% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $106.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $180.00K 10-K · filed 2026-03-31 | |
| 2025-06-30 | $82.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $107.00K 10-K · filed 2026-03-31 | |
| 2024-06-30 | $59.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $182.00K 10-K · filed 2026-03-31 | |
| 2023-06-30 | $131.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $174.00K 10-K · filed 2025-03-27 | |
| 2022-06-30 | $64.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $484.00K 10-K · filed 2024-03-28 | |
| 2021-06-30 | $305.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |